Tags : Meningococcal Meningitis

Sanofi Reports FDA’s Acceptance of BLA for MenQuadfi to Prevent

Tuba Khan June 27, 2019

Shots: The FDA’s acceptance of BLA for review follows P-II & P-III study assessing MenQuadfi in patients aged ≥ 2yrs. conducted in the US MenQuadfi is currently evaluated in P-II […]readmore

Tags : Meningococcal Meningitis

Sanofi Reports FDA’s Acceptance of BLA for MenQuadfi to Prevent

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Meningococcal Meningitis

﻿Sanofi Reports FDA’s Acceptance of BLA for MenQuadfi to Prevent

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Sanofi Reports FDA’s Acceptance of BLA for MenQuadfi to Prevent